Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

60.50 +1.22 (+2.06%)
Delayed Quote Updated: 3:59 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Q2 Earnings Outperformers: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns ↗
Via Chartmill
News headline image
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate. 
Via The Motley Fool
News headline image
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗
You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance. 
Via The Motley Fool
News headline image
2 Profitable Stocks to Target This Week and 1 We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) ↗
If you are looking for yield and can think long-term, you'll want to consider Bristol Myers Squibb and Realty Income today. 
Via The Motley Fool
Topics Bonds Intellectual Property
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
Which S&P500 stocks are moving on Monday? ↗
Via Chartmill
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
3 Value Stocks We Steer Clear Of
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
3 Dirt Cheap Dividend Stocks Worth Buying in October ↗
There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin. 
Via The Motley Fool
Topics Economy
News headline image
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale ↗
Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years. 
Via The Motley Fool
News headline image
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NAS... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories. 
Via The Motley Fool
News headline image
Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now ↗
Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation ↗
With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 Facing Challenges
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple. 
Via The Motley Fool
News headline image
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗
Pharmaceutical company share prices may suffer, but probably not by as much as some might fear. 
Via The Motley Fool
Topics Bonds Economy
News headline image
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? ↗
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗
The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.